Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Wednesday, August 13, 2025, inter-alia considered and approved the following:1. Unaudited Financial Results:The Unaudited Financial Results for the Quarter ended June 30, 2025. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015.2. Approved revision/change in the following Policy/Code: Nomination and Remuneration Policy. Policy on Determination of Materiality of Events Code of Conduct to Regulate, Monitor and Report on Trading in Securities by Insiders.The Meeting of the Board of Directors of the Company commenced at 03:30 p.m. and concluded at 04.10 p.m.Kindly take the above information on your records.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience's board, at its meeting on August 13, 2025, approved the unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations stood at ₹1,450.74 million, down from ₹1,606.26 million in Q1 FY25 — a year-on-year decline of about 9.7%. Profit after tax fell to ₹347.90 million from ₹446.44 million, a ~22% drop, with EPS at ₹4.32 vs ₹5.54. Statutory auditors Kakaria and Associates issued an unqualified limited review report. The board also revised three policies: Nomination & Remuneration, Materiality of Events, and Insider Trading Code. No exceptional items were reported.
Lower revenue and a sharper fall in profits signal margin pressure in the quarter, which may weigh on the stock in the short term. Investors should watch for management commentary on demand and pricing to gauge if the softness is temporary.